Skip to main content
Report this ad

See also:

Zontivity approved to reduce the danger of heart attacks in high risk patients

Zontivity (vorapaxar) is a new class of drugs called protease-activated receptor-1 (PAR-1) antagonist.
Getty Images/file photo
Report this ad